Q3 2024 VolitionRX Ltd Earnings Call Transcript
Key Points
- VolitionRX Ltd (VNRX) reported significant growth in sales of their Nu.Q Vet cancer tests, with over 110,000 tests sold in the first three quarters of 2024, nearly double the total sales of 2023.
- The company's revenue growth is accelerating, with a year-to-date increase of 100% and a quarterly increase of 307% compared to the same periods in 2023.
- VolitionRX Ltd (VNRX) has expanded the availability of its Nu.Q Vet cancer test to 17 countries, enhancing its global market presence.
- The company has successfully reduced operating expenses by 28% compared to the same quarter last year, contributing to a 36% reduction in cash used in operating activities.
- VolitionRX Ltd (VNRX) has secured commitments for over $2.2 million in non-dilutive funding from agencies within the Walloon region, Belgium, supporting its financial stability.
- Despite the revenue growth, VolitionRX Ltd (VNRX) acknowledges that revenue can be lumpy at this stage, making it difficult to provide meaningful revenue guidance.
- The company is still working towards achieving cash neutrality by 2025, indicating ongoing financial challenges.
- VolitionRX Ltd (VNRX) has not yet achieved the milestone for feline testing, as they are still optimizing the test for cats.
- The company faces challenges in commercializing its human cancer tests, with ongoing studies and data publications yet to be completed.
- VolitionRX Ltd (VNRX) is heavily reliant on securing licensing deals in the human clinical space to achieve its financial goals, which introduces uncertainty.
To withdraw your question. Please press the star key, followed by the number two. If you're using speaker equipment, please lift the handset before making your selection. This conference is being recorded today. November 15th, 2024. I would now like to turn the conference call over to Louis Batchelor Group, Chief Marketing and Communications Officer. Please go ahead.
Thank you and welcome everyone to today's conference call for volition Rx limited.
Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1,995.
These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us because these statements reflect our current views concerning future events. These statements involve risks, uncertainties and assumptions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
